BeneFIX: Uses, Dosage & Side Effects
Recombinant coagulation factor IX (nonacog alfa) for the treatment and prevention of bleeding episodes in patients with hemophilia B (Christmas disease)
BeneFIX (nonacog alfa) is a recombinant coagulation factor IX produced using recombinant DNA technology. It is used for the treatment and prevention of bleeding in patients of all ages with hemophilia B (also known as Christmas disease), a rare inherited bleeding disorder caused by a deficiency or absence of functional coagulation factor IX. BeneFIX works by replacing the missing factor IX, enabling the blood to clot normally. It is administered as an intravenous injection after reconstitution and is available exclusively by prescription. BeneFIX has been a cornerstone of hemophilia B management since its approval, providing patients with a safe, virus-free recombinant alternative to plasma-derived factor IX products.
Quick Facts: BeneFIX
Key Takeaways
- BeneFIX (nonacog alfa) is a recombinant factor IX replacement therapy used to treat and prevent bleeding in patients with hemophilia B (Christmas disease), a rare X-linked bleeding disorder affecting approximately 1 in 25,000 male births worldwide.
- It is administered by intravenous injection and must be reconstituted from a freeze-dried powder before use; the reconstituted solution should be used within 3 hours and should never be administered by continuous infusion (drip).
- Allergic reactions, including life-threatening anaphylaxis, are possible; initial treatments should be given under medical supervision, and patients should be monitored for the development of neutralizing antibodies (inhibitors) to factor IX.
- Dosing is individualized based on the patient's weight, severity of the bleeding episode, location of the bleed, and the desired factor IX activity level; a higher dose may be needed compared with plasma-derived factor IX products.
- BeneFIX must be stored at or below 30°C, must not be frozen, and should be protected from light; it is manufactured by Pfizer and is approved by the EMA, FDA, and regulatory authorities worldwide.
What Is BeneFIX and What Is It Used For?
BeneFIX is an injectable product containing coagulation factor IX manufactured through recombinant DNA technology. The active substance in BeneFIX is nonacog alfa, a recombinant form of human coagulation factor IX. People born with hemophilia B (also called Christmas disease, named after Stephen Christmas, the first patient described with this condition in 1952) lack sufficient coagulation factor IX to control bleeding. BeneFIX works by replacing the deficient factor IX in hemophilia B patients, enabling their blood to clot normally and effectively.
Hemophilia B is a rare, inherited X-linked recessive bleeding disorder that predominantly affects males. It results from mutations in the F9 gene located on the X chromosome, leading to reduced production or impaired function of coagulation factor IX. The condition affects approximately 1 in 25,000 male births worldwide, according to the World Federation of Hemophilia (WFH). Factor IX plays a critical role in the intrinsic coagulation pathway: when activated by factor XIa (or by the tissue factor/factor VIIa complex in the extrinsic pathway), factor IXa forms a complex with activated factor VIII (FVIIIa) on phospholipid surfaces in the presence of calcium ions. This tenase complex then activates factor X, which ultimately leads to thrombin generation and the formation of a stable fibrin clot.
Without adequate levels of functional factor IX, patients with hemophilia B experience prolonged bleeding after injuries, surgery, or dental procedures. In severe cases (factor IX activity below 1% of normal), spontaneous bleeding can occur, particularly into joints (hemarthrosis) and muscles. Repeated joint bleeds lead to hemophilic arthropathy, a debilitating chronic joint disease that significantly impairs quality of life. Moderate hemophilia B (factor IX activity 1–5%) typically presents with bleeding after minor trauma, while mild hemophilia B (factor IX activity 5–40%) may only cause excessive bleeding after surgery or significant injury.
BeneFIX is approved by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and regulatory authorities in numerous other countries for the treatment and prevention of bleeding episodes in patients with hemophilia B across all age groups. It can be used in several clinical contexts:
- On-demand treatment: BeneFIX is used to treat acute bleeding episodes when they occur, restoring factor IX levels to achieve hemostasis. The dose is tailored to the severity and location of the bleed.
- Prophylaxis: Regular, scheduled infusions of BeneFIX can be used to prevent bleeding episodes, particularly in patients with severe hemophilia B. Prophylactic therapy has been shown to reduce the frequency of joint bleeds and slow the progression of hemophilic arthropathy.
- Perioperative management: BeneFIX is used before, during, and after surgical procedures to maintain adequate factor IX levels and prevent excessive bleeding in hemophilia B patients.
BeneFIX was first approved by the FDA in 1997 and has since become one of the most widely used recombinant factor IX products globally. As a recombinant product, BeneFIX is manufactured without the use of human blood or plasma, eliminating the risk of transmission of blood-borne infectious agents such as HIV and hepatitis viruses—a critical advantage over earlier plasma-derived factor IX concentrates. The manufacturing process involves Chinese hamster ovary (CHO) cell lines, which is why trace amounts of hamster protein may be present in the final product.
BeneFIX is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. This means the factor IX protein is manufactured in a laboratory setting rather than being purified from donated human blood plasma. This approach virtually eliminates the risk of transmitting blood-borne viruses, which was historically a significant concern with plasma-derived clotting factor concentrates.
What Should You Know Before Taking BeneFIX?
Before starting treatment with BeneFIX, it is essential that your healthcare provider is fully informed about your medical history, current medications, and any allergies. Several important factors must be considered to ensure the safe and effective use of this medication. Your doctor will weigh the benefits of factor IX replacement therapy against the potential risks specific to your individual clinical situation.
Contraindications
BeneFIX must not be used if you have a known allergy (hypersensitivity) to nonacog alfa or to any of the other ingredients in the product, including sucrose, glycine, L-histidine, and polysorbate 80. Additionally, BeneFIX must not be used if you are allergic to hamster proteins. Because BeneFIX is manufactured in Chinese hamster ovary (CHO) cells, trace amounts of hamster protein may be present in the final product. If you have experienced an allergic reaction to any factor IX product in the past, inform your doctor before receiving BeneFIX.
Potentially life-threatening anaphylactic reactions have occurred with factor IX products, including BeneFIX. Early signs of allergic reactions include difficulty breathing, shortness of breath, swelling, hives (which may be widespread), itching, chest tightness, wheezing, low blood pressure, blurred vision, and anaphylaxis (a severe allergic reaction that can cause difficulty swallowing and/or breathing, flushing or swelling of the face and/or hands). If any of these symptoms occur, stop the injection immediately and seek emergency medical care.
Warnings and Precautions
Speak with your doctor or pharmacist before using BeneFIX. There are several important warnings and precautions associated with this medication that you should be aware of:
- Inadequate response to treatment: Contact your doctor promptly if bleeding does not stop as expected. A failure to respond to treatment may indicate the development of factor IX inhibitors.
- Allergic and anaphylactic reactions: Allergic reactions are possible with BeneFIX. The product may contain trace amounts of hamster proteins. Anaphylactic reactions have been reported with factor IX products, including BeneFIX. If allergic or anaphylactic reactions occur, discontinue the injection immediately and contact your doctor or seek emergency care. If severe allergic reactions occur, alternative therapy should be considered.
- Inhibitor development: Previously treated patients receiving factor IX products may develop neutralizing antibodies (inhibitors), although this is less common than with factor VIII products. Your factor IX inhibitor status should be carefully monitored during treatment. There is a reported association between the occurrence of factor IX inhibitors and allergic reactions. If you experience allergic reactions, you should be tested for the presence of inhibitors. Patients with factor IX inhibitors may be at higher risk of anaphylaxis with subsequent BeneFIX infusions.
- Gene mutations: Patients with specific mutations in the factor IX gene, such as large deletion mutations, may be more susceptible to developing inhibitors and/or having allergic reactions. If you are known to have such a mutation, your doctor may monitor you more closely, especially when you first begin treatment with BeneFIX.
- Medical supervision for initial doses: Due to the risk of allergic reactions, your first infusions of BeneFIX should be administered under medical supervision where appropriate medical treatment for allergic reactions is available.
- Dose adjustments: Even in the absence of inhibitors, a higher dose of BeneFIX may be needed compared with other plasma-derived factor IX products you may have used previously. Careful monitoring of plasma factor IX activity (which measures your blood's ability to clot) must be performed to adjust the dose appropriately. If bleeding is not controlled with the recommended dose, contact your doctor.
- Liver or heart disease: If you have liver or heart disease, or if you have recently undergone surgery, there is an increased risk of thromboembolic complications (blood clot formation).
- Nephrotic syndrome: Kidney dysfunction (nephrotic syndrome) has been reported following high doses of plasma-derived factor IX in hemophilia B patients with factor IX inhibitors who previously had allergic reactions.
It is recommended that you record the product name and batch number each time you use BeneFIX. You can use one of the peel-off labels on the vial to document the batch number in your diary or for reporting any adverse reactions.
Drug Interactions
Inform your doctor or pharmacist if you are taking, have recently taken, or might take any other medications. No specific drug interactions with BeneFIX have been identified in clinical studies. However, as with any coagulation factor replacement therapy, the concomitant use of antifibrinolytic agents (such as tranexamic acid or aminocaproic acid) should be managed carefully, as the combination of clot-forming and clot-stabilizing agents may increase the risk of thromboembolic events in certain clinical situations.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, you should only use BeneFIX on the advice of your doctor. It is not known whether BeneFIX can cause harm to an unborn baby when given to a pregnant woman. Since hemophilia B is an X-linked recessive disorder, it predominantly affects males. The need for factor IX replacement therapy in pregnant women is extremely rare. Your doctor can advise you on the risks and benefits of using BeneFIX during pregnancy or breastfeeding.
Driving and Operating Machinery
BeneFIX has no known effect on the ability to drive or operate machinery. There are no restrictions on activities after infusion, beyond the general recommendations related to the management of hemophilia B.
After reconstitution, BeneFIX contains 0.2 mmol (4.6 mg) sodium per vial, meaning it is essentially sodium-free. However, depending on your body weight and prescribed dose, you may receive multiple vials per treatment session. This should be taken into consideration if you are on a controlled sodium diet.
How Does BeneFIX Interact with Other Drugs?
BeneFIX (nonacog alfa) has not been shown to interact with specific medications in clinical trials. Unlike many small-molecule drugs that are metabolized through hepatic cytochrome P450 enzyme pathways, BeneFIX is a recombinant protein that is processed and cleared through the same physiological mechanisms as endogenous factor IX. As a result, traditional drug-drug interactions mediated by enzyme induction or inhibition are not expected.
Nevertheless, there are important pharmacological considerations when BeneFIX is used alongside other medications that affect the coagulation cascade or vascular integrity. Patients with hemophilia B often require multidisciplinary care, and coordinating all treatments through a specialized hemophilia treatment center is strongly recommended.
Important Considerations
| Medication/Class | Interaction Type | Clinical Significance |
|---|---|---|
| Antifibrinolytics (tranexamic acid, aminocaproic acid) | Additive pro-coagulant effect | Increased risk of thromboembolic events when used concurrently. Caution advised; monitor for signs of thrombosis. |
| Anticoagulants (warfarin, heparin, DOACs) | Opposing pharmacological effects | Anticoagulants may reduce the hemostatic efficacy of factor IX replacement. Dose adjustments may be necessary in rare clinical scenarios. |
| Antiplatelet agents (aspirin, clopidogrel) | Complex effect on hemostasis | Antiplatelet agents may alter bleeding risk. Use with caution and under specialist guidance in hemophilia patients. |
| NSAIDs (ibuprofen, naproxen) | Impaired platelet function | NSAIDs may increase bleeding tendency. Use COX-2 selective inhibitors or paracetamol as alternatives when possible. |
| Emicizumab (bispecific antibody) | Additive coagulation effect | Note: Emicizumab is indicated for hemophilia A, not hemophilia B. If used in a patient also receiving factor IX, specialist oversight is required. |
It is important to note that patients with hemophilia should generally avoid intramuscular injections of other medications, as these can cause significant muscle hematomas. Subcutaneous or intravenous routes of administration are preferred whenever possible. Always consult your hemophilia treatment center or specialist physician before starting or stopping any medications.
What Is the Correct Dosage of BeneFIX?
Always use BeneFIX exactly as your doctor or pharmacist has instructed. The dose and duration of treatment depend on your individual need for factor IX replacement therapy and on how quickly your body uses up (clears) factor IX, which will be monitored regularly through blood tests. You may notice a difference in the dose you receive if you switch from a plasma-derived factor IX product to BeneFIX, as the incremental recovery of recombinant factor IX may differ from plasma-derived products.
The required dose of BeneFIX is calculated using the following general formula (though your doctor will determine the exact approach):
Required IU = Body weight (kg) × Desired factor IX increase (% or IU/dL) × Reciprocal of observed recovery (IU/kg per IU/dL)
The average incremental recovery of BeneFIX is approximately 0.7–0.8 IU/dL per IU/kg in adults and may be lower in children. Your doctor will use your individual recovery data to calculate your specific dose.
Dosage by Bleeding Type
| Type of Bleeding | Target Factor IX Level | Dosing Frequency | Duration |
|---|---|---|---|
| Minor (early joint bleed, minor muscle bleed, oral bleeding) | 20–30 IU/dL | Every 12–24 hours | At least 1 day, until bleeding resolves |
| Moderate (joint bleed, muscle bleed, hematoma, minor trauma) | 25–50 IU/dL | Every 12–24 hours | 3–5 days or until adequate healing |
| Major (life-threatening bleeds, intracranial, gastrointestinal, retroperitoneal) | 60–100 IU/dL | Every 8–24 hours | 7–10 days or until adequate healing |
| Surgery (minor procedures) | 30–60 IU/dL | Every 24 hours | Until healing is complete (5–7 days) |
| Surgery (major procedures) | 80–100 IU/dL (pre- and post-operative) | Every 8–24 hours | Until adequate healing (10–14 days or longer) |
Adults
In adults, the median incremental recovery of BeneFIX is approximately 0.7–0.8 IU/dL per IU/kg body weight administered. This means that for a 70 kg adult, a dose of approximately 50 IU/kg would be expected to raise the plasma factor IX level by approximately 35–40 IU/dL. The elimination half-life in adults is typically 18–34 hours, allowing for dosing intervals of 12–24 hours for most clinical situations. For prophylactic regimens, typical doses range from 25–40 IU/kg administered twice weekly, though your doctor will individualize your prophylaxis schedule.
Children
Children may require higher doses per kilogram of body weight compared with adults because the pharmacokinetics of factor IX differ in the pediatric population. Younger children tend to have a shorter half-life, higher clearance rates, and lower incremental recovery for factor IX. Clinical studies have shown that the incremental recovery in children under 15 years of age may be approximately 20–30% lower than in adults. As a result, pediatric patients often need more frequent dosing or higher individual doses to achieve and maintain target factor IX levels. Your child's hemophilia treatment center will closely monitor factor IX activity levels to optimize the dosing regimen.
Elderly
There are limited data on the use of BeneFIX in elderly patients (over 65 years). As with all factor IX replacement therapy, dosing in older patients should be individualized based on clinical response, factor IX recovery measurements, and the presence of any comorbid conditions such as liver disease, cardiovascular disease, or renal impairment. Elderly patients may have an increased risk of thromboembolic complications, particularly if they have additional cardiovascular risk factors. Close monitoring is recommended.
Reconstitution and Administration
BeneFIX is supplied as a freeze-dried (lyophilized) powder that must be reconstituted with the supplied solvent (0.234% sodium chloride solution) in a pre-filled syringe before administration. The reconstitution process involves the following key steps:
- Allow the vial of BeneFIX powder and the pre-filled syringe of solvent to reach room temperature.
- Remove the plastic cap from the vial and clean the rubber stopper with the provided alcohol swab.
- Attach the vial adapter to the top of the vial by pressing firmly through the rubber stopper.
- Connect the pre-filled syringe of solvent to the vial adapter and slowly push the plunger to transfer all solvent into the vial.
- Gently swirl the vial until the powder is completely dissolved. Do not shake vigorously.
- Inspect the solution visually: it should be clear and colorless. Do not use if it appears cloudy or contains particles.
- Invert the vial and slowly draw the reconstituted solution into the syringe.
- Administer by intravenous injection over several minutes at a rate comfortable for the patient.
BeneFIX should be administered immediately after reconstitution or within 3 hours. The reconstituted solution should be kept at room temperature. It must never be administered as a continuous infusion (drip), as this method has not been evaluated and has been associated with serious thromboembolic complications, including life-threatening blood clots in critically ill neonates receiving BeneFIX through central venous catheters.
There have been reports of red blood cell clumping (agglutination) in the tubing or syringe during BeneFIX administration. No adverse reactions have been reported as a result. To minimize this risk, limit the amount of blood entering the tubing. Blood should not enter the syringe. If red blood cell agglutination is observed, discard all affected materials (tubing, syringe, and BeneFIX solution) and continue administration with a new package.
Missed Dose
If you are on a prophylactic regimen and miss a scheduled dose, administer the dose as soon as you remember, then resume your regular dosing schedule. Do not double the dose to compensate for a missed infusion. Contact your hemophilia treatment center if you are unsure about how to proceed after missing a dose.
Overdose
Contact your doctor immediately if you have injected more BeneFIX than recommended. While no cases of overdose with BeneFIX have been formally reported, excessively high factor IX levels could theoretically increase the risk of thromboembolic events (blood clot formation). Patients with liver disease, post-operative patients, and neonates may be at particular risk. Treatment of overdose would be supportive and focused on managing any thromboembolic complications that may arise.
Do not stop using BeneFIX without consulting your doctor. Abrupt discontinuation of prophylactic therapy could lead to breakthrough bleeding episodes, which may be severe depending on the underlying severity of your hemophilia B.
What Are the Side Effects of BeneFIX?
As with all coagulation factor products, BeneFIX may cause side effects. It is important to be aware of these potential adverse reactions so that you can recognize them early and seek appropriate medical attention. The overall safety profile of BeneFIX has been well established through extensive clinical trials and post-marketing surveillance involving thousands of patients worldwide.
Allergic and Hypersensitivity Reactions
Allergic reactions are possible with BeneFIX and may range from mild local reactions at the infusion site to severe systemic reactions including anaphylaxis. Symptoms may include facial or throat swelling, burning and stinging at the infusion site, chills, flushing, itching, headache, hives, low blood pressure, lethargy, nausea, restlessness, rapid heart rate, chest tightness, tingling, vomiting, and wheezing. In some cases, these reactions have progressed to severe anaphylaxis. Allergic reactions have been observed in temporal association with the development of factor IX inhibitors. If any allergic or anaphylactic reactions occur, stop the infusion immediately and contact your doctor or seek emergency medical care.
Inhibitor Development
Patients with hemophilia B may develop neutralizing antibodies (inhibitors) against factor IX. Signs of inhibitor development include needing an increased amount of BeneFIX to control bleeding or continued bleeding despite treatment. If inhibitors develop, a specialized hemophilia center should be contacted. Patients with inhibitors may also be at increased risk of severe allergic reactions, including anaphylaxis.
Thromboembolic Events
BeneFIX may increase the risk of thrombosis (blood clot formation) in patients with risk factors for blood clots. An indwelling venous catheter may also be a risk factor for thrombosis. Reports of serious thrombotic events, including life-threatening blood clots in critically ill neonates who received BeneFIX via continuous infusion through a central venous catheter, have been documented. Cases of peripheral thrombophlebitis (pain and redness of veins) and deep vein thrombosis have also been reported. In most cases, BeneFIX had been administered by continuous infusion (drip), which is not an approved method of administration.
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- Headache
- Cough
- Fever
Common
May affect up to 1 in 10 people
- Hypersensitivity/allergic reactions
- Dizziness, altered taste
- Phlebitis (pain and redness of veins), flushing
- Vomiting, nausea
- Skin rash, hives (urticaria)
- Chest discomfort (including chest pain)
- Infusion site reactions (including itching and redness at the infusion site), pain and discomfort at the infusion site
Uncommon
May affect up to 1 in 100 people
- Development of neutralizing antibodies (inhibitors)
- Cellulitis at the infusion site (pain and redness of the skin)
- Fatigue, shaking (tremor)
- Visual disturbances (including blurred vision, spots, and light streaks)
- Rapid heart rate (tachycardia), low blood pressure (hypotension)
- Renal infarction (blockage of blood flow to the kidney)
Not Known
Frequency cannot be estimated from available data
- Anaphylactic reaction
- Thrombotic events (abnormal blood clots)
- Lack of therapeutic response (failure to stop or prevent bleeding episodes)
If you experience any side effects, including those not listed above, talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national pharmacovigilance reporting system. By reporting side effects, you can help provide more information on the safety of this medicine.
Seek emergency medical care immediately if you experience any signs of a severe allergic reaction (difficulty breathing, swelling of the face or throat, severe hives, drop in blood pressure, loss of consciousness) or signs of a blood clot (sudden pain, swelling, warmth, or redness in an arm or leg; sudden chest pain or shortness of breath; sudden severe headache or confusion). These are serious, potentially life-threatening conditions requiring immediate treatment.
How Should You Store BeneFIX?
Proper storage of BeneFIX is essential to maintain the potency and safety of the product. Incorrect storage can lead to degradation of the factor IX protein, reducing its effectiveness and potentially causing adverse reactions.
- Temperature: Store BeneFIX at or below 30°C (86°F). The product can be stored at room temperature, which makes it convenient for home storage and travel.
- Do not freeze: BeneFIX must not be frozen, as freezing may damage the pre-filled syringe containing the solvent.
- Expiration date: Use before the expiration date printed on the outer carton and vial label. The expiration date refers to the last day of the indicated month.
- After reconstitution: The reconstituted solution should be used immediately, but no later than 3 hours after preparation. Store the reconstituted solution at room temperature prior to administration.
- Visual inspection: Do not use BeneFIX if the reconstituted solution is not clear and colorless. Any solution that appears cloudy, contains particles, or has changed color should be discarded.
- Solvent syringe: Only use the pre-filled syringe supplied with the package for reconstitution. Other sterile disposable syringes may be used for administration.
- Keep out of reach of children: Store this medicine out of the sight and reach of children.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. These measures help to protect the environment.
BeneFIX can be stored at up to 30°C, making it suitable for travel without the need for cold chain storage. When traveling, keep BeneFIX in its original packaging and protect it from direct sunlight and extreme temperatures. Carry a letter from your hemophilia treatment center confirming your need for the medication, especially when traveling internationally.
What Does BeneFIX Contain?
Understanding the composition of BeneFIX is important for patients who may have allergies or intolerances to specific ingredients. The complete composition of the product is detailed below.
Active Substance
The active substance is nonacog alfa (recombinant coagulation factor IX). Each vial of BeneFIX contains a nominal amount of 250, 500, 1000, 1500, 2000, or 3000 IU of nonacog alfa. After reconstitution with the supplied 5 mL solvent, the resulting concentrations are as follows:
| Vial Strength | Concentration After Reconstitution |
|---|---|
| 250 IU | 50 IU/mL |
| 500 IU | 100 IU/mL |
| 1000 IU | 200 IU/mL |
| 1500 IU | 300 IU/mL |
| 2000 IU | 400 IU/mL |
| 3000 IU | 600 IU/mL |
Other Ingredients (Excipients)
- Sucrose – a sugar used as a stabilizer to protect the factor IX protein during the freeze-drying process
- Glycine – an amino acid used as a buffering agent and stabilizer
- L-histidine – an amino acid used as a buffering agent to maintain the optimal pH of the solution
- Polysorbate 80 – a surfactant that helps maintain the stability of the protein in solution
Solvent
The solvent supplied for reconstitution is a 0.234% sodium chloride solution (5 mL) provided in a pre-filled syringe with a plunger rod.
Package Contents
Each package of BeneFIX contains:
- One vial of BeneFIX powder (250, 500, 1000, 1500, 2000, or 3000 IU)
- One pre-filled syringe containing 5 mL of 0.234% sodium chloride solution for reconstitution, with plunger rod
- One sterile vial adapter for reconstitution
- One sterile infusion set
- Two alcohol swabs
- One adhesive bandage (plaster)
- One gauze pad
Manufacturer
BeneFIX is manufactured by Wyeth Farma S.A., Autovia del Norte A-1, Km 23, Desvio Algete, Km 1, 28700 San Sebastian de los Reyes, Madrid, Spain. The marketing authorization holder is Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Brussels, Belgium.
Frequently Asked Questions About BeneFIX
Hemophilia B (also called Christmas disease) is a rare inherited bleeding disorder caused by a deficiency or absence of coagulation factor IX. It is an X-linked recessive condition, meaning it predominantly affects males. Without sufficient factor IX, the blood cannot clot properly, leading to prolonged or spontaneous bleeding episodes. BeneFIX provides the missing factor IX through intravenous injection, allowing the blood to clot normally and preventing or treating bleeding episodes. It is used for both on-demand treatment of acute bleeds and as regular prophylaxis to prevent bleeding.
Yes, many patients with hemophilia B learn to self-infuse BeneFIX at home after receiving proper training from their hemophilia treatment center. Home treatment allows for faster treatment of bleeding episodes and is essential for prophylactic therapy. However, your initial infusions should always be given under medical supervision to monitor for allergic reactions. Your healthcare team will teach you the proper technique for reconstituting the powder, performing venipuncture, and administering the injection. It is important to keep a treatment diary recording the date, batch number, dose, and any adverse reactions.
If your bleeding does not stop as expected after receiving BeneFIX, contact your doctor or hemophilia treatment center immediately. A lack of response may indicate the development of neutralizing antibodies (inhibitors) against factor IX. Your doctor will perform laboratory tests to check your factor IX levels and screen for inhibitors. If inhibitors are confirmed, your treatment plan will need to be modified, potentially involving the use of bypassing agents or immune tolerance induction therapy. Do not increase your dose without medical guidance.
Yes, BeneFIX is approved for use in patients of all ages, including children and infants. However, children may require higher doses per kilogram of body weight compared with adults because they tend to have faster factor IX clearance and lower recovery rates. Pediatric dosing is individualized based on the child's weight, factor IX levels, and clinical response. The same safety precautions apply to children as to adults, including monitoring for allergic reactions and inhibitor development. Your child's hemophilia treatment center will develop an appropriate dosing plan.
No, BeneFIX should not be mixed with other medications or infusion solutions. Continuous infusion (drip) of BeneFIX has not been evaluated and must not be performed. BeneFIX should only be reconstituted with the supplied 0.234% sodium chloride solvent using the provided vial adapter. Mixing with other solutions could affect the stability and activity of the factor IX protein, reduce effectiveness, or increase the risk of adverse reactions. Always use the product as directed in the prescribing information.
BeneFIX is a recombinant product, meaning it is manufactured in a laboratory using genetically engineered cells (Chinese hamster ovary cells) rather than being purified from donated human blood plasma. The key advantage of recombinant products is the virtual elimination of the risk of transmitting blood-borne infectious agents such as HIV and hepatitis viruses. However, the pharmacokinetics may differ: BeneFIX typically has a lower incremental recovery compared with some plasma-derived products, which means a higher dose may be needed to achieve the same factor IX level. Your doctor will adjust your dose based on your individual response.
References
- European Medicines Agency (EMA). BeneFIX Summary of Product Characteristics. Available at: www.ema.europa.eu. Last updated 2025.
- U.S. Food and Drug Administration (FDA). BeneFIX Prescribing Information. Pfizer Inc. Available at: www.fda.gov. Revised 2024.
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. doi:10.1111/hae.14046
- Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX – formulation and delivery. Blood Coagulation & Fibrinolysis. 1998;9 Suppl 1:S37-S40.
- Mannucci PM, Franchini M. Recombinant factor IX: Achievements, remaining challenges, and future directions. Blood. 2014;124(25):3675-3682. doi:10.1182/blood-2014-07-570218
- World Federation of Hemophilia (WFH). Report on the Annual Global Survey 2022. Montreal: WFH; 2023.
- British National Formulary (BNF). Coagulation Factor IX – Nonacog alfa. Available at: bnf.nice.org.uk. Accessed January 2026.
- International Society on Thrombosis and Haemostasis (ISTH). Guidelines on laboratory aspects of assays used in hemophilia and other bleeding disorders. Journal of Thrombosis and Haemostasis. 2023;21(8):2113-2129.
- Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. New England Journal of Medicine. 2013;369(24):2313-2323. doi:10.1056/NEJMoa1305074
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
Medical Editorial Team
Clinical Hematology Specialist
Board-certified hematologist with expertise in bleeding disorders and coagulation factor therapies
Clinical Pharmacologist
Specialist in pharmacokinetics and pharmacodynamics of biological medicinal products
Medical Writer
Experienced medical writer specializing in hematology and rare diseases
Quality Reviewer
Independent medical reviewer ensuring accuracy according to EMA, FDA, and WFH guidelines
All content is reviewed according to international medical standards (WHO, EMA, FDA, WFH, ISTH). Evidence level: 1A based on systematic reviews, randomized controlled trials, and international clinical guidelines. No pharmaceutical company funding or sponsorship.